OPTIME Therapeutics, Inc operated as a biopharmaceutical company developing liposome delivery technology. The company had been working on drugs for dry-eye syndrome, glaucoma, conjunctivitis, postoperative pain and uveitis. The firm's endeavors organized around the topical delivery of drug products to the skin, lungs, or mucosal membranes using multilamellar liposomes. Liposomes are composed of phospholipids and have the ability to encapsulate selected drug molecules and enhance their therapeutic safety and efficacy by beneficially altering the distribution and kinetics of the molecule in the body, following its administration through various routes of delivery. Topical delivery of drugs avoids whole body exposure and unwanted side effects commonly observed following oral administration, thereby increasing the therapeutic profile of the drug. In February 2007, Optime Therapeutics, Inc. filed a voluntary petition to reorganize under Chapter 11 in the US Bankruptcy Court for the Northern District of California. Subsequently, all patents and technology of Optime Therapeutics were acquired by the pharmaceutical company Lippomix.
